Çağla BÜYÜKBOZAT, Serhan KÜPELİ, Şeyda ERDOĞAN, Gülay SEZGİN, İbrahim BAYRAM

Nöroblastom hastalarında telomeraz aktivitesinin prognoz ile ilişkisi

Amaç: Bu çalışmanın amacı, telomeraz aktivitesinin nöroblastomlu hastaların klinik özellikleri ve sağkalımı üzerindeki etkisini araştırmaktı. Gereç ve Yöntem: Bu çalışma, Çukurova Üniversitesi Tıp Fakültesi Pediatrik Onkoloji Anabilim Dalı'nda 2011-2019 yılları arasında nöroblastom tanısı konulan 87 hastanın daha önce alınan patoloji preparatlarında telomeraz aktivitesi incelenerek yapılmıştır. Bulgular: Çalışmamıza 46'sı erkek (%52.9) ve 41'i kadın (%47.1) olmak üzere toplam 87 hasta dahil edildi. Tanı anındaki ortanca yaş 3.0 (0.08-15) yıldı. Çalışmaya alınan 23 (%26.4) hastada telomeraz aktivitesi mevcutken 64 (%73.6) hastada telomeraz aktivitesi yoktu. 8 yıla kadar telomeraz aktivitesi olan hastaların genel sağkalımı (OS) %84 iken olaysız sağkalım (EFS) %56 idi. Telomeraz aktivitesi olmayan hastalar 8 yıla kadar %93 OS'ye sahipken, EFS %70 idi. Telomeraz aktivitesi olan ve olmayan hastalar arasında cinsiyet, yaş, evre, risk grubu, relaps, mycn amplifikasyonu, OS ve EFS açısından anlamlı bir ilişki yoktu. Sonuç: Bu çalışmada, telomeraz aktivitesi ile nöroblastom hastalarının klinik özellikleri ve sağkalımları arasında anlamlı bir fark bulunmadı. Daha fazla sayıda hastanın dahil edileceği prospektif çalışmalar telomeraz aktivitesinin nöroblastom hastalarının prognozu üzerine etkisini daha net bir şekilde ortaya koyacaktır.

Relationship of telomerase activity with prognosis in patients with neuroblastoma

Purpose: The aim of this study was to investigate the effect of telomerase activity on clinical characteristics and survival of patients with neuroblastoma. Materials and Methods: This study was carried out by examining telomerase activity in previously taken pathology preparations of 87 patients who were diagnosed with neuroblastoma between 2011 and 2019 in the Pediatric Oncology Department of Çukurova University Faculty of Medicine. Results: Totally 87 patients, 46 males (52.9%) and 41 females (47.1%), were included in our study. Median age at the time of diagnosis was 3.0 (0.08-15) years. Twenty-three (26.4%) patients included in the study had telomerase activity, 64 (73.6%) had no telomerase activity. Overall survival (OS) of patients with telomerase activity up to 8 years were 84%, while event-free survival (EFS) was 56%. Patients without telomerase activity had a 93% OS for up to 8 years, while EFS was 70%. There was no significant relationship between patients with or without telomerase activity in terms of sex, age, stage, risk group, relapse, myc- n amplification, OS and EFS. Conclusions: In this study, no significant difference was found between telomerase activity and clinical features and survival of neuroblastoma patients. Prospective studies involving larger numbers of patients will more clearly demonstrate the impact of telomerase activity on the prognosis of patients with neuroblastoma.

PDF

___

1. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma In: Principles and Practice of Pediatric Oncology (Eds PA Pizzo, D Poplack):886- 889. Philadelphia, Lippincott Williams & Wilkins, Philadelphia, 2011.
2. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incident and Survival among Children and Adolescents: United States SEER Program, 1975- 1995. National Cancer Institute, Bethesda, 1999; 35.
3. Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11:704-13.
4. Landuzzi L, Strippoli P, Giovanni CD, Nicoletti G, Rossi I, Tonelli R et al. Production of stem cell factor and ezpression of Ckit in human rhabdomtosarcoma cells: Lack of autocrine growth modulation. Int J Cancer. 1998;78:441-5.
5. Küpeli S, Arkan A, İncecik F, Altunbaşak Ş. Telomerase activity in patients with neurofibromatosis type-1. Cukurova Med J. 2018;43:167-72.
6. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S, Greider CW. Human telomerase RNA and telomerase activity tumor tissues. Cancer Res. 1996;56:645-50.
7. Sharma S, Chowdhury S. Emerging mechanisms of telomerase reactivation in cancer. Trends Cancer. 2022; doi: 10.1016/j.trecan.2022.03.005.
8. Quazi S. Telomerase gene therapy: a remission toward cancer. Med Oncol. 2022;39:105.
9. Piette C, Dresse MF, Forget P, Schmitz V, Demarche M, Erpicum P et al. Clinical evaluation of 23 children with neuroblastoma. The experience of a single institution. Rev Med Liege. 2005;60:173–80.
10. Simon T. Neuroblastoma. Urol Ausg A. 2005;44:543– 55.
11. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526:700–4.
12. Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Ichikawa T, Shay JW et al. Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? Eur J Cancer. 1997;33:1932–6.
13. Nozaki C, Horibe K, Iwata H, Ishiguro Y, Hamaguchi M, Takahashi M. Prognostic impact of telomerase activity in patients with neuroblastoma. Int J Oncol. 2000;17:341–5.
14. Kebudi R, Bayram I, Yagci-Kupeli B, Kupeli S, Sezgin G, Pekpak E et al. Refugee children with cancer in Turkey. Lancet Oncol. 2016;17:865-67.